However, 3 large prospective double-blinded randomized placebo-controlled trials of statins in CAVD failed to show any retardation of its progression.[4–6] The similar result was obtained from the clinical trial of angiotensin-converting enzyme inhibitors.[3] In our study, the CCR1, which had the highest MCC score, was identified as hub genes in CAVD. The gene discussed is CCR1; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.